FOLH1 and prostate carcinoma: Over the last few years, the prostate-specific membrane antigens (PSMA), which are enzymes and receptors on the surface of prostatic cells and also known as glutamate carboxypeptidase II, have widely attracted attentions as a target for imaging and treating patients with prostate cancer.